Lyudmila Bazhenova, MD, Discusses Potential for Trials Featuring Combination IO/Targeted Therapy for EGFR Exon 20+ and Wild Type NSCLC

Video

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Lyudmilia Bazhenova, MD, of University of California at San Diego, about why she would not recommend conducting another trial utilizing a single agent immune checkpoint inhibitor in wild-type and EGFR exon 20 insertion non–small cell lung cancer. However, she noted that there may be potential for a trial utilizing immunotherapy plus a lung cancer vaccine.

Transcript:

At this point I’m not aware of any of any trial, and I would be reluctant to do the trial with traditionally approved checkpoint inhibition because I think it’s unlikely that they’re going to work. If we would have a combinatorial immunotherapy trial of maybe a combination of lung cancer vaccines and immunotherapy, I think one can envision doing it. [However], in my practice, I do not use checkpoint inhibition for those patients, and I don’t think I would be comfortable enrolling the patient to a monotherapy immune checkpoint inhibition trial.

Reference

Bazhenova L, Girard N, Minchom A, et al. Comparative clinical outcomes between EGFR Exon20ins and wildtype NSCLC treated with immune checkpoint inhibitors. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Accessed September 27, 2021. Abstract P08.04

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
4 experts in this video
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Related Content